Abstracts Archive - Page 1432 of 2425 - ACR Meeting Abstracts

Abstract Number: 211 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Febuxostat in Advanced CKD Patients with Hyperuricemia
Yoon-Jeong Oh¹, Seung Min Jung¹, Sang-Won Lee², Yong-Beom Park² and Jason Jungsik Song², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Dosing adjustments and increased risk of serious side effects of uric acid lowering agents in patients with reduced renal function lead to undercorrection of…
Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting
Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Brian F. Mandell¹, Michael Weisman², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…
Abstract Number: 213 • 2016 ACR/ARHP Annual Meeting
Prophylaxis for Infusion Reactions to Pegloticase: An Analyis of Two Different Corticosteroid Pre-Infusion Regimens in US Community Rheumatology Practices
Amar Majjhoo¹, Kome Okposo² and Michael Zdanis³, ¹Shores Rheumatology, St. Clair Shores, MI, ²Horizon Pharma, Lake Forest, IL, ³Cetus Group, LLC, Towson, MD
Background/Purpose: Corticosteroids are commonly utilized, along with other agents in clinical practice for pre-infusion prophylaxis prior to the administration of therapeutic biologic proteins. Two steroids,…
Abstract Number: 214 • 2016 ACR/ARHP Annual Meeting
Anakinra Compared to Prednisone on the Treatment of Acute CPPD Crystal Arthritis, a Randomized, Controlled, Double-Blind Study
Alexandre Dumusc¹, Borbala Pazar Maldonado¹, Charles Benaim², Isabelle Fabreguet¹, Pascal Zufferey¹, Bérengère Aubry-Rozier¹ and Alexander So¹, ¹Rheumatology Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland, ²Physical Medicine and Rehabilitation Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland
Background/Purpose: Calcium pyrophosphate crystal-induced arthritis (CPPD) is an acute crystal arthritis, frequently involving the wrist or the knee. Monosodium urate in gout or CPPD…
Abstract Number: 215 • 2016 ACR/ARHP Annual Meeting
Anakinra Is Effective and Well Tolerated in Medically Complex Patients Including Transplant Recipients with Gout
Christopher Palma¹, Taylor Topping² and Darren Tabechian¹, ¹Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Pharmacy, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Anakinra is a biologic response modifier that competitively antagonizes the biologic effects of interleukin-1β. Conventional treatments for the inflammatory response to acute gout are…
Abstract Number: 216 • 2016 ACR/ARHP Annual Meeting
Colchicine Prescribing As a Parameter for QA/QI Process in Gout Care
Peter A. Valen¹, Maren Mahowald², Anne Westgard³, Melissa Atwood^4,5 and Hollis Krug⁶, ¹Rheumatology/ Dept of Medicine, Minneapolis VA and Univ MN Med School, Minneapolis, MN, ²Rheumatology/ Dept of Medicine, Minneapolis VA and Univ MN Med School, SAINT PAUL, MN, ³Rheumatology, VA Med Center MPLS, Minneapolis, MN, ⁴Medicine, Minneapolis VA Health Care System, Minneapolis, MN, ⁵Pharmacy, Minneapolis VA HCS, Minneapolis, MN, ⁶Medicine, Minneapolis VA and Univ MN Med School, Minneapolis, MN
Background/Purpose: Because of the large increase in the price of colchicine with the FDA granted market exclusivity the Pharmacy at the Mpls VA HCS asked…
Abstract Number: 217 • 2016 ACR/ARHP Annual Meeting
The Effect of Regular Treatment on Disability in a Cohort of Patients with Gout.
Janitzia Vazquez-Mellado^1,2, Carlos O Lopez Lopez³, Citlallyc Gomez-Ruiz⁴, Everardo Alvarez-Hernandez⁴, Ingris Pelaez-Ballestas⁴, Ruben Burgos-Vargas^2,5 and Aaron Vazquez-Mellado⁴, ¹Facultad de Medicina, UNAM, Professor, Mexico city, Mexico, ²Rheumatology, Hospital General de México, Mexico City, Mexico, ³Rehabilitation, Hospital General de Mexico, Mexico city, Mexico, ⁴Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁵Universidad Nacional Autonoma de Mexico, Mexico, Mexico
Background/Purpose: The severity of gout is often associated with poor patient compliance and sub-optimal medical treatment. Our objective was to determine the prevalence, characteristics, and…
Abstract Number: 218 • 2016 ACR/ARHP Annual Meeting
Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture
Stephanie Fabre¹, Jean-Marie Launay¹, Jean-François Gautier¹, Adam Platt², Jeffrey N. Miner³, Glen Hughes², Pascal Richette⁴ and Thomas Bardin¹, ¹Hôpital Lariboisière, Paris, France, ²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ³Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ⁴Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: A key factor in the success of gout management is the long-term lowering of serum uric acid (sUA) levels below predetermined targets (5 or…
Abstract Number: 219 • 2016 ACR/ARHP Annual Meeting
Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol
Nicola Dalbeth¹, Savvas Nicolaou², Scott Baumgartner³, Jia Hu³, Maple Fung³ and Hyon K. Choi⁴, ¹University of Auckland, Auckland, New Zealand, ²Radiology, University of British Columbia, Vancouver, BC, Canada, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic hyperuricemia predisposes to deposition of monosodium urate (MSU) crystals in musculoskeletal and other tissues, causing chronic inflammation, acute gout flares, joint damage, and…
Abstract Number: 220 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout
Siddharth K. Das¹, Harikrishnan Velayudhan², Danveer Bhadu³, Urmila Dhakad⁴ and Ragini Srivastava⁵, ¹Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, ²Rheumatology, Senior Resident, Rheumatology, K.G. Medical University, Lucknow, India, Luknow, India, ³Rheumatology, Senior Resident III, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, ⁴Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India, ⁵Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India
Background/Purpose: Detection of double contour sign (DCS) and hyperechoic aggregates (HAG) is a reliable method in detecting urate crystal deposition by ultrasound (US) which has…
Abstract Number: 221 • 2016 ACR/ARHP Annual Meeting
Ultrasound in Gout: The Clinical Application
Ching-Tsai Lin¹, Chong Hong Lim^2,3, Yi-Hsing Chen^4,5 and D.Y. Chen^5,6,7, ¹Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ²Rheumatology Unit, Department of Medicine, Hospital Pulau Pinang, Georgetown, Malaysia, ³Division of Allergy, immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁴Divisions of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁵School of Medicine, National Yang-Ming University, Taipei, Taiwan, ⁶Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan
Background/Purpose: The utility of ultrasound (US) in aiding the diagnosis of gout has been well established. The latest 2015 gout classification criteria have included the…
Abstract Number: 222 • 2016 ACR/ARHP Annual Meeting
Role of Synovial Biopsy in Diagnosis of Crystal Arthropathies
Viju Moses¹, Jaya Asirvatham², Jonathan McHugh² and Robert Ike¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Pathology, University of Michigan, Ann Arbor, MI
Title: Role of Synovial Biopsy in Diagnosis of Crystal Arthropathies Background/Purpose: Diagnosis of crystal arthropathies (CAs) can be challenging. Advances in arthroscopy and ultrasound guided…
Abstract Number: 223 • 2016 ACR/ARHP Annual Meeting
Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York
Lara El Khoury¹, Mohamad Yasmin^1,2, Nabil Zeineddine¹, Joseph Saabiye¹, Saleha Riaz¹, Sami Arnaout¹, Talal El Imad¹, Suzanne El-Sayegh³ and Rita Obeid⁴, ¹Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, NY, ²Infectious Diseases, Case Western Reserve University, Cleveland, OH, ³Internal Medicine, Program Director, Staten Island University Hospital, Northwell Health, Staten Island, NY, ⁴Psychology, The Graduate Center, CUNY, New York, NY
Background/Purpose: Gout is the most prevalent inflammatory arthritis worldwide. Within the healthcare setting, gout flares contribute to substantial morbidity and complicated hospital stays. Identifying risk…
Abstract Number: 224 • 2016 ACR/ARHP Annual Meeting
Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study
Angelo L. Gaffo¹, Nicola Dalbeth², Kenneth G. Saag³, Jasvinder Singh³, Elizabeth J. Rahn¹, Amy S. Mudano³, Tuhina Neogi⁴, Lorenzo Cavagna⁵, Yi-Hsing Chen⁶, Ching-Tsai Lin⁷, Worawit Louthrenoo⁸, Geraldo Castelar-Pinheiro⁹, Fernando Perez-Ruiz¹⁰, Janitzia Vazquez-Mellado¹¹, Maxim Eliseev¹², Lisa K. Stamp¹³ and William Taylor¹⁴, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁸Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁹Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ¹⁰Servicio de Reumatología, Vizcaya, Spain, ¹¹Rheumatology, Hospital General de México, Mexico City, Mexico, ¹²Research Institute of Rheumatology of Russia, Moscow, Russian Federation, ¹³University of Otago, Christchurch, New Zealand, ¹⁴University of Otago, Wellington, New Zealand
Patient Perception of Gout Flares as a Measure of Outcome: Results from an International Study Background/Purpose: Attacks (flares) are one of the primary manifestations of…
Abstract Number: 225 • 2016 ACR/ARHP Annual Meeting
Patterns of Joint Involvement in Gout Flares
Ana Beatriz Vargas-Santos¹, Yuqing Zhang², Na Lu¹, Nicola Dalbeth³, William J. Taylor⁴, Jaap Fransen⁵, Tim Jansen⁶, H. Ralph Schumacher Jr.⁷ and Tuhina Neogi¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴Department of Medicine, University of Otago, Wellington, New Zealand, ⁵Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁶VieCuri Medical Center, Venlo, Netherlands, ⁷Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: Gout flares are the most common manifestations of gout. Awareness of possible disease presentations beyond the traditionally recognized podagra is essential for accurate and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].